Sun Pharma Advanced Research Company Limited (BOM:532872)
134.95
-1.95 (-1.42%)
At close: Feb 12, 2026
BOM:532872 Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Equivalents | - | 19.64 | 53.3 | 5.84 | 12.24 | 93.05 |
Short-Term Investments | - | - | 1,500 | 1,110 | - | - |
Trading Asset Securities | - | - | 18.01 | 2,909 | 116.65 | 64.25 |
Cash & Short-Term Investments | 9.4 | 19.64 | 1,571 | 4,025 | 128.89 | 157.3 |
Cash Growth | -84.51% | -98.75% | -60.96% | 3022.58% | -18.06% | 77.87% |
Accounts Receivable | - | 160.57 | 184.03 | 362.31 | 305.65 | 175.76 |
Other Receivables | - | 23.59 | 399.22 | 28.25 | 0.26 | 0 |
Receivables | - | 185.78 | 585.46 | 395.95 | 309.25 | 176.44 |
Inventory | - | 19.54 | 14.79 | 10.66 | 10.78 | 7.96 |
Prepaid Expenses | - | 35.97 | 48.19 | 33.28 | 24.76 | 47.91 |
Other Current Assets | - | 1.04 | 474.11 | 85.02 | 237.84 | 241.51 |
Total Current Assets | - | 261.97 | 2,694 | 4,550 | 711.52 | 631.11 |
Property, Plant & Equipment | - | 992.55 | 1,086 | 1,073 | 951.18 | 951.08 |
Other Intangible Assets | - | 536.53 | 427.12 | 254.68 | 231.16 | 6.85 |
Long-Term Deferred Tax Assets | - | 23.09 | 12.62 | - | - | - |
Other Long-Term Assets | - | 1,541 | 930.67 | 2,424 | 906.97 | 707.86 |
Total Assets | - | 3,355 | 5,150 | 8,301 | 2,801 | 2,297 |
Accounts Payable | - | 1,139 | 1,423 | 1,483 | 721.87 | 911.68 |
Accrued Expenses | - | 228.71 | 374 | 175.93 | 147.37 | 155.73 |
Short-Term Debt | - | 1,582 | 470 | 0.51 | - | 800 |
Current Portion of Long-Term Debt | - | - | - | - | 750 | 380.45 |
Current Portion of Leases | - | 37.99 | 34.9 | 30.04 | 17.77 | 16.21 |
Current Income Taxes Payable | - | 4.43 | 16.47 | - | - | - |
Current Unearned Revenue | - | 408.98 | 0 | 0.01 | 0.29 | 2.7 |
Other Current Liabilities | - | 341.2 | 332.29 | 100.44 | 76.99 | 66.74 |
Total Current Liabilities | - | 3,742 | 2,651 | 1,789 | 1,714 | 2,334 |
Long-Term Debt | - | 1,000 | - | - | - | 1,125 |
Long-Term Leases | - | 69.49 | 106.61 | 126.2 | 24.37 | 42.15 |
Long-Term Unearned Revenue | - | 625.98 | 1,035 | 1,176 | 668.45 | 392.43 |
Pension & Post-Retirement Benefits | - | 22.42 | - | 11.32 | 18.82 | 29.22 |
Other Long-Term Liabilities | - | 64.52 | 100.74 | 70.06 | 62.65 | 57.1 |
Total Liabilities | - | 5,525 | 3,893 | 3,174 | 2,489 | 3,979 |
Common Stock | - | 324.53 | 324.53 | 324.53 | 271.89 | 262.06 |
Additional Paid-In Capital | - | 20,382 | 20,382 | 20,382 | 11,064 | 9,405 |
Retained Earnings | - | -22,876 | -19,449 | -15,578 | -13,366 | -11,349 |
Comprehensive Income & Other | - | 0.68 | 0.07 | - | 2,343 | - |
Shareholders' Equity | -3,446 | -2,169 | 1,258 | 5,128 | 312.26 | -1,683 |
Total Liabilities & Equity | - | 3,355 | 5,150 | 8,301 | 2,801 | 2,297 |
Total Debt | 4,166 | 2,689 | 611.51 | 156.75 | 792.14 | 2,364 |
Net Cash (Debt) | -4,157 | -2,670 | 959.8 | 3,868 | -663.25 | -2,207 |
Net Cash Growth | - | - | -75.19% | - | - | - |
Net Cash Per Share | -12.81 | -8.23 | 2.96 | 13.59 | -2.52 | -8.42 |
Filing Date Shares Outstanding | 324.27 | 324.52 | 324.52 | 324.52 | 271.88 | 262.05 |
Total Common Shares Outstanding | 324.27 | 324.52 | 324.52 | 324.52 | 271.88 | 262.05 |
Working Capital | - | -3,480 | 43.28 | 2,760 | -1,003 | -1,702 |
Book Value Per Share | -10.63 | -6.69 | 3.88 | 15.80 | 1.15 | -6.42 |
Tangible Book Value | -4,160 | -2,706 | 830.44 | 4,873 | 81.1 | -1,689 |
Tangible Book Value Per Share | -12.83 | -8.34 | 2.56 | 15.02 | 0.30 | -6.45 |
Land | - | 80.35 | 80.35 | 80.35 | 80.35 | 80.35 |
Buildings | - | 310.4 | 308.55 | 303.62 | 300.07 | 273.69 |
Machinery | - | 1,000 | 993.88 | 887.9 | 854.83 | 774.81 |
Construction In Progress | - | 5.61 | 12.69 | 18.73 | 37.2 | 52.34 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.